Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 5.3% in October

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) saw a large decrease in short interest in the month of October. As of October 15th, there was short interest totalling 17,610,000 shares, a decrease of 5.3% from the September 30th total of 18,600,000 shares. Based on an average daily trading volume, of 648,300 shares, the short-interest ratio is presently 27.2 days.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of large investors have recently made changes to their positions in KPTI. Exchange Traded Concepts LLC lifted its stake in shares of Karyopharm Therapeutics by 34.9% during the 3rd quarter. Exchange Traded Concepts LLC now owns 218,791 shares of the company’s stock worth $182,000 after acquiring an additional 56,613 shares during the last quarter. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics during the second quarter worth $31,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Karyopharm Therapeutics during the second quarter valued at $494,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Karyopharm Therapeutics in the 2nd quarter worth about $143,000. Finally, AQR Capital Management LLC increased its holdings in Karyopharm Therapeutics by 494.5% during the 2nd quarter. AQR Capital Management LLC now owns 748,020 shares of the company’s stock worth $649,000 after purchasing an additional 622,194 shares during the period. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Price Performance

Shares of KPTI opened at $0.99 on Friday. The stock has a market capitalization of $123.41 million, a price-to-earnings ratio of -0.84 and a beta of 0.20. Karyopharm Therapeutics has a 1 year low of $0.62 and a 1 year high of $1.95. The business’s 50 day simple moving average is $0.80 and its 200-day simple moving average is $0.92.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.09. The business had revenue of $42.79 million for the quarter, compared to the consensus estimate of $36.07 million. On average, sell-side analysts expect that Karyopharm Therapeutics will post -0.93 earnings per share for the current year.

Analysts Set New Price Targets

KPTI has been the topic of a number of recent analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, August 7th. StockNews.com upgraded shares of Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Robert W. Baird cut their target price on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $5.00.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).